"Cyclophosphamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
| Descriptor ID |
D003520
|
| MeSH Number(s) |
D02.455.526.728.650.730.243 D02.705.672.500.243
|
| Concept/Terms |
Cyclophosphamide- Cyclophosphamide
- Cytophosphane
- Cyclophosphamide Monohydrate
- Monohydrate, Cyclophosphamide
- Cyclophosphane
|
Below are MeSH descriptors whose meaning is more general than "Cyclophosphamide".
Below are MeSH descriptors whose meaning is more specific than "Cyclophosphamide".
This graph shows the total number of publications written about "Cyclophosphamide" by people in this website by year, and whether "Cyclophosphamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2011 | 0 | 2 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 2 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 2 | 2 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclophosphamide" by people in Profiles.
-
Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation. Am J Hematol. 2025 Jun; 100(6):987-997.
-
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. Clin Lymphoma Myeloma Leuk. 2022 11; 22(11):847-852.
-
Abatacept-based Graft-Versus-Host Disease Prophylaxis in Haplo-identical Hematopoietic Cell Transplant in a High-risk Cohort. J Pediatr Hematol Oncol. 2022 10 01; 44(7):383-387.
-
Outcomes of cardiac diffuse large B-cell lymphoma (DLBCL) in the rituximab era. Int J Cardiol. 2021 Sep 15; 339:146-149.
-
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis. Oncoimmunology. 2021 01 25; 10(1):1859263.
-
Ovarian antibodies among SLE women with premature menopause after cyclophosphamide. Int J Rheum Dis. 2021 Jan; 24(1):120-124.
-
Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. Clin Cancer Res. 2021 03 01; 27(5):1278-1286.
-
Perspectives on chemotherapy for the management of double-hit lymphoma. Expert Opin Pharmacother. 2020 Apr; 21(6):653-661.
-
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clin Cancer Res. 2020 03 01; 26(5):1025-1033.
-
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study. Blood Adv. 2019 06 25; 3(12):1815-1825.